Company · Healthcare
Every investor coverage indicates participated in a round US Cystic Fibrosis Foundation raised.
Companies US Cystic Fibrosis Foundation acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming US Cystic Fibrosis Foundation. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Brandon Capital's blog profiles Respirion, interviewing founders Barry Clements and Matt Callahan plus investment manager Helga Mikkelsen about the company's inhaled cystic fibrosis therapy, now in a Phase 2a trial.
A Telethon Kids spin-out backed by Brandon Capital has begun trials in the US and Australia of RSP-1502, an inhaled antibiotic booster for cystic fibrosis lung infections, after strong early results in WA patients.
A Telethon Kids offshoot, Respirion Pharmaceuticals, is trialling its antibiotic-booster therapy RSP-1502 in the US and Australia, with backing from Brandon Capital and an American cystic fibrosis foundation.